Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call …

Nov 7, 2024 · Revenue: $33.3 million in Q3 2024, up from $22.5 million in Q3 2023. US Revenue: $23.3 million, accounting for 70% of product revenue, an 8% increase sequentially. …

CouponFollow Extension

70%
OFF

Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call …

1 week from now

Nov 7, 2024 · Revenue: $33.3 million in Q3 2024, up from $22.5 million in Q3 2023. US Revenue: $23.3 million, accounting for 70% of product revenue, an 8% increase sequentially. …

yahoo.com

$33
OFF

Transcript : Rhythm Pharmaceuticals, Inc., Q3 2024 Earnings Call, …

1 week from now

Nov 5, 2024 · Earnings Flash (RYTM) RHYTHM PHARMACEUTICALS Posts Q3 Revenue $33.3M Nov. 05: MT Rhythm Pharmaceuticals, Inc. Reports Earnings Results for the Third …

marketscreener.com

48%
OFF

Rhythm Pharmaceuticals Third Quarter 2024 Earnings: Beats …

1 week from now

Nov 7, 2024 · Rhythm Pharmaceuticals (NASDAQ:RYTM) Third Quarter 2024 ResultsKey Financial Results. Revenue: US$33.3m (up 48% from 3Q 2023). Net loss: US$45.0m (loss …

yahoo.com

$0.73
OFF

Rhythm Pharmaceuticals (RYTM) Earnings Date And Reports 2024

1 week from now

4 days ago · Rhythm Pharmaceuticals issued Q3 2024 earnings on November 5, 2024, reporting an EPS of -$0.73, which topped analysts' consensus estimates of -$0.80 by $0.07. Quarterly …

marketbeat.com

FAQs about Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call … Coupon?

Does Rhythm Pharmaceuticals (Rytm) beat earnings expectations in Q3 2024?

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) Q3 2024 Earnings Call Transcript November 5, 2024 Rhythm Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.73, expectations were $-0.8. Operator: Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Third Quarter 2024 Earnings Conference Call. ...

What did Rhythm Pharmaceuticals do in Q3 2024?

ET -- BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the third quarter ended September 30, 2024. ...

How did Rhythm Pharmaceuticals (Rytm) perform in Q3?

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) reported strong revenue growth with third-quarter revenues reaching $33.3 million, a 14% increase from the previous quarter. The company is making significant progress in its clinical programs, with the phase three trial for hypothalamic obesity on track for a data readout in the first half of 2025. ...

What is the Rhythm Pharmaceuticals Investor Relations website?

The Investor Relations website contains information about Rhythm Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. ...

Who is Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. ...

Why did Rhythm Pharmaceuticals reduce its 2024 operating expense guidance?

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) has reduced its 2024 operating expense guidance, indicating improved operating leverage and financial management. The company experienced a slight increase in cost of sales, primarily due to higher labor and overhead costs. ...